CytoSorbents Corp. on Tuesday said it has reappointed Kathleen Bloch as full-time chief financial officer, effective retroactively to Sept. 2.
Bloch served as the Princeton-based firm’s CFO for 10 years until her retirement in March, when she became interim CFO as a consultant. She resumed as interim CFO after CytoSorbents terminated CFO Alexander D’Amico.
Phillip Chan, CEO of CytoSorbents, stated: “Following this unexpected turn of events, it is great to have Kathy back as full-time chief financial officer. Kathy’s accomplished career speaks for itself. We thank Kathy for her unquestioned dedication to the company, the management team and our employees over the past decade, and, particularly now, as we enter this exciting time for the company. Kathy’s commitment secures this leadership position and provides the time and expertise to focus and execute upon our critical near-term business goals and priorities.”
Bloch stated, “The next six to 12 months is expected to bring a potential wealth of opportunities as we target U.S. and Canadian approval for the first time with DrugSorb-ATR, and we work to capitalize on both anticipated improvements in the acute care markets and investments made with our existing CytoSorb business. Like the rest of this outstanding team, I am passionate about our mission to help save lives and am proud of the company we have built to date. It was an easy decision to come back and provide continuity and stability to our company and business at this pivotal moment.”